Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Starling Oncology, Inc.
Report date April 21, 2026 · Filed April 24, 2026
Section 16 reporting ended · disclosed 2026-04-24. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2026 Filed Apr 2, 2026 01:00 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 70,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-26-000449 · ownership.xml · nonDerivative · entry 1 Langsam Jeffrey · CIK 0002069752 · Chief Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,650 F1 · shares: Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| May 21, 2025 Filed May 23, 2025 17:02 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 57,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000935836-25-000396 · ownership.xml · nonDerivative · entry 1 Langsam Jeffrey · CIK 0002069752 · Chief Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,380 F1 · shares: Represents RSU awards that were fully vested upon grant, net of withholding tax obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.